Articles related to PRECISION MEDICINE

“The test is designed to assess a patient’s individualized risk of sentinel lymph node positivity and recurrence or metastasis, integrating tumor biology with clinical and pathological features via a validated proprietary algorithm.”

The results of PROfound and PROpel underscore the importance of identifying the genomic characteristics of the patient and the cancer to guide the selection of the most appropriate treatment for a specific patient type.

The prevalence of HRR deficiencies has been found to be as high as 20% to 30% in patients with mCRPC, a significantly higher rate than that in patients with localized disease.

Patients whose disease has progressed on osimertinib or other EGFR tyrosine kinase inhibitors (TKIs) without emergent T790M or other targetable alterations can receive platinum-based chemotherapy with or without amivantamab.

Although genomic classifier tests for prostate cancer show promise, a systematic review of 22 studies reveals marked differences between observational and trial data in how these tests influence risk stratification and treatment selection.

Latest clinical trial data suggests active monitoring may be a viable alternative to standard treatment for select low-risk DCIS patients, with comparable quality-of-life outcomes.